A new topical medication, Eucrisa, for treating eczema has recently been approved by the FDA. With keen interest I read every word of the backup study and publication in the Journal of the American Academy of Dermatology concerning then named Opa-15406, a novel topical non-steroidal PDE4 inhibitor. The study included patients who had just recently [...]
A physician, Tim Berger, presented a poster at the recent March, 2017, Academy of Dermatology meeting. In essence he implies that he discovered TSA, TSW and RSS with the caveat that these patients itch. It is evident that he never saw any of the patients, since this was only a survey from the internet. The [...]
The Dupilumab studies were 16 weeks long. This is a very short time to truly evaluate a drug in this very difficult and prolonged skin problem. In addition, there were no objective comments on rash, redness, skin oozing, edema and pain. There are no long term follow ups reported. But: Links to patient comments after [...]
My most recent postings have dissected the protocol, the patients, the methods and the fine print of the Dupilumab studies reported in the medical literature. Severe failings are evident in all the above criteria. What, therefore can we expect from the results and conclusions? This assessment will group together all Dupilumab studies. My findings are: [...]
The Dupilumab studies as reported in the New England Journal of Medicine and the Journal of the American Academy of Dermatology and by me on discussed in my four prior posts exhibit multiple violations in the study of new drugs and scientific reporting. Inclusion of patients: from my experience with 4000 totally similar patients none [...]
Recent Comments